{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:51:56Z","timestamp":1740124316118,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10585-023-10263-1","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T11:01:46Z","timestamp":1706439706000},"page":"461-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant therapy for resectable melanoma"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-3297","authenticated-orcid":false,"given":"Cimarron E.","family":"Sharon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgos C.","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"10263_CR1","doi-asserted-by":"publisher","first-page":"175883592210830","DOI":"10.1177\/17588359221083052","volume":"14","author":"RG Witt","year":"2022","unstructured":"Witt RG, Erstad DJ, Wargo JA (2022) Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol 14:17588359221083052. https:\/\/doi.org\/10.1177\/17588359221083052","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10263_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"03","author":"AC Huang","year":"2019","unstructured":"Huang AC, Orlowski RJ, Xu X et al (2019) A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 03(3):454\u2013461. https:\/\/doi.org\/10.1038\/s41591-019-0357-y","journal-title":"Nat Med"},{"issue":"11","key":"10263_CR3","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","volume":"11","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA et al (2018) Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 11(11):1649\u20131654. https:\/\/doi.org\/10.1038\/s41591-018-0197-1","journal-title":"Nat Med"},{"issue":"11","key":"10263_CR4","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","volume":"11","author":"CU Blank","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF et al (2018) Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 11(11):1655\u20131661. https:\/\/doi.org\/10.1038\/s41591-018-0198-0","journal-title":"Nat Med"},{"issue":"7","key":"10263_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"07","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ et al (2019) Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 07(7):948\u2013960. https:\/\/doi.org\/10.1016\/S1470-2045(19)30151-2","journal-title":"Lancet Oncol"},{"issue":"7","key":"10263_CR6","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","volume":"07","author":"RN Amaria","year":"2019","unstructured":"Amaria RN, Menzies AM, Burton EM et al (2019) Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 07(7):e378\u2013e389. https:\/\/doi.org\/10.1016\/S1470-2045(19)30332-8","journal-title":"Lancet Oncol"},{"issue":"2","key":"10263_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"02","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA et al (2021) Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 02(2):301\u2013309. https:\/\/doi.org\/10.1038\/s41591-020-01188-3","journal-title":"Nat Med"},{"issue":"2","key":"10263_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","volume":"02","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Prieto PA, Tetzlaff MT et al (2018) Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 02(2):181\u2013193. https:\/\/doi.org\/10.1016\/S1470-2045(18)30015-9","journal-title":"Lancet Oncol"},{"issue":"7","key":"10263_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","volume":"07","author":"GV Long","year":"2019","unstructured":"Long GV, Saw RPM, Lo S et al (2019) Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF. Lancet Oncol 07(7):961\u2013971. https:\/\/doi.org\/10.1016\/S1470-2045(19)30331-6","journal-title":"Lancet Oncol"},{"key":"10263_CR10","doi-asserted-by":"crossref","unstructured":"Blank C, Irene L, Reijers R et al (2022) Survival data of PRADO: a phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol p. 9501","DOI":"10.1200\/JCO.2022.40.16_suppl.9501"},{"key":"10263_CR11","unstructured":"Adjuvant treatment determined by pathological response to neoadjuvant nivolumab. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04013854"},{"issue":"9","key":"10263_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"02","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y et al (2023) Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in Advanced Melanoma. N Engl J Med Mar 02(9):813\u2013823. https:\/\/doi.org\/10.1056\/NEJMoa2211437","journal-title":"N Engl J Med Mar"},{"key":"10263_CR13","unstructured":"Neoadjuvant PD-1 blockade in patients with stage IIB\/C melanoma. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03757689"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10263-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T15:14:21Z","timestamp":1725462861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10263-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10263"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10263-1","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"type":"print","value":"0262-0898"},{"type":"electronic","value":"1573-7276"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"25 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Giorgos Karakousis is a PI of an Investigator-Initiated Trial with institutional support by Merck and serves on the Merck advisory board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}